Complete heparin-coated extracorporeal circuits, including cardiotomy reservoir, have recently become available for routine cardiac surgery. The effects on complement and granulocyte activation using a heparin-coated circuit in combination with reduced systemic heparinization (activated clotting time (ACT) >250 s) were studied in 33 patients undergoing elective first time myocardial revascularization. The patients were prospectively randomized either to a heparin-coated group (Group H, n = 17), or to a control group (Group C, n = 16) treated with an identical uncoated circuit and full heparin dose (ACT > 480 s). During cardiopulmonary bypass (CPB) the C3 activation products C3b, iC3b, and C3c (C3bc) and the terminal SC5b-9 complement complex (TCC) increased markedly in both groups compared to baseline, but to a much lesser extent in the heparin-coated group. The maximal increase of C3bc during the operation was a median of 28 arbitrary units (AU)/ml in the heparin-coated group, compared to 45 AU/ml in the control group (P = 0.01). Similarly, in Group H the maximal increase of TCC was significantly lower (median 0.8 AU/ml) than the levels recognized in Group C (median 1.9 AU/ml) (P < 0.0001). The release of the granulocyte activation enzymes lactoferrin and myeloperoxidase also increased during CPB in both groups compared to baseline level. The maximal increase of lactoferrin concentration was a median of 229 gg/1 in Group H and significantly lower than 647 gg/1 in the control group (P = 0.0002). As for myeloperoxidase, there were no significant intergroup differences. In conclusion, a complete heparin-coated circuit and low systemic heparinization for CPB in coronary artery surgery were associated with reduced activation of the complement system and less release of lactoferrin. The results indicate improved biocompatibility of this option for extracorporeal circulation. [Eur J Cardio-thorac Surg (1996) 10: 54-60] 
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Introduction
Several experimental and clinical studies on heparincoated extracorporeal circuits have demonstrated reduced activation of the complement, the coagulation and fibrinolytic systems, as well as white blood cells and platelets [2, 6, 10, 11, 26, [32] [33] [34] . However, most studies have been performed in the situation where only the oxygenator and tubing set were heparin-coated. In 1993 complete heparincoated equipment for extracorporal circulation, including the cardiotomy reservoir, became available for routine cardiac surgery.
It has been suggested that complement activation, especially the formation of the terminal SC5b-9 complement complex (TCC), as well as the activation of neutrophils are relevant indicators of the biocompatibility of artificial surfaces [5, 6, 22] . The purpose of the present study was to investigate the effects of heparin-coated circuits on the most relevant complement activation markers, as well as on activation of granulocytes assessed by the release of myeloperoxidase and lactoferrin, in patients undergoing elective coronary artery bypass surgery. All surfaces in contact with the patients' blood were coated with end-point attached covalently bounded heparin (Carmeda Bio-Active Surface, CBAS)a. The extracorporeal setting was identical to ordinary cardiopulmonary bypass (CPB) equipment, with the use of cardiotomy suction and reservoir. The systemic heparin and protamine volumes were reduced to one third of the normal dose.
Material and methods
Patients admitted for elective coronary artery bypass surgery with two-or three-vessel disease were eligible for the study. Exclusion criteria were urgent operation, redo surgery, age more than 75 years, and impaired left ventricular function. Neurological disorders and liver and renal failure were also reasons for exclusion, as were anticoagulation or antiplatelet therapy.
Thirty-three patients entered the study and were randomly allocated to have CPB with either a heparm-coated circuit 2 (Group H, n = 17) or an identical but uncoated circuit, the latter serving as a control group (Group C, n = 16). No visual differences of the two extracorporal circuits were present, and the randomization was blinded to the surgical team. Informed consents were obtained from all patients, and the study protocol was approved by the regional Ethical Commltte. All operations were performed by one of two surgeons (E.O, G.T.).
Heparin-coated group (Group H)
All surfaces in contact with blood were heparin-coated. The circuit included polyvinylchloride tubings connected to a hard shell cardiotomy reservoir (CB SK 1351), a collapsible venous reservoir bag (CB MVR 1600), a woven hollow polypropylene fiber membrane oxygenator (CB Maxima Plus 3380) and a 20 gm arterial filter (CB m-20). Systemic heparm (Heparin) 3 was given in a bolus dose of 100 IU/kg, with a target acttvated clotting time (ACT) 4 of 250 s before the institution of bypass. The dose of protamine sulphate for neutralization of heparin was 1.3 rag/100 IU heparin. The extracorporeal bypass circuit was disconnected before the administration of protamine.
Control group (Group C)
The extracorporeal circuit was uncoated but otherwise Identical to that of Group H. Heparin was given in the standard dosage, i.e. In both groups, additional heparin was given if the ACT level was below the lower limit. In the postoperative period, an ACT of more than 130 s indicated supplemental protamine administration.
Operation and blood conservation
The extracorporal circulation was performed using a StBckert roller pump and pulsatile flow at a rate of 2 4 l/m: per min. Moderate hypothermia (blood temperature: 32 °C) was instituted immediately after the start of bypass. The heart-lung machine was primed with 2000 ml of Ringer's acetate and hemodllution was even more accentuated by autologous blood removal for blood conservation (see below), which aimed at an intraoperative hematocrit of more than 22 %. The ventilation of the lungs was terminated when the patient was on CPB. and reinstituted a few minutes before the conclusion of bypass.
Myocardial protection consisted of the antegrade administration of crystalloid cardaoplegia (St. Thomas' Hospital No. 2) and topical cooling with ice slush. The proximal anastomoses were sutured during partial occlusion of the ascending aorta. Cardiotomy suction was utilized deliberately during the entire period of heparinization. Surgical hemostasis was completed before reversal of the anticoagulation with protamine sulphate. The Institution's blood conservation protocol [24] was applied in all cases, including autologous blood removal before bypass with later retransfusion. For autotransfuslon of mediastlnal shed blood postoperatively, the medlastinal and pleural tubes were connected to the hard-shell cardlotomy reservoir used during the extracorporeal circulation, and the shed blood was autotransfused hourly in a closed system up to 18 h after the operation.
Test blood sampling
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood samples were drawn from the central venous cannula at the following intervals: 1) after induction of anesthesia, 2) immediately following institution of CPB, 3) after release of the aortic cross-clamping, 4) at the end of CPB, after onset of lung ventilation, 5) 2 mm after administration ofprotamiue, 6) 2 h and 7) 18 h postoperatively. All samples were immediately cooled on ice and centrifuged, and the plasma stored at a temperature of-70 °C until assayed in one batch. The analyses were performed blinded with regard to allocation of the patients to the two groups Analysis C3 activation was measured in a double antibody enzyme immunoassay (EIA) [71. The polystrene plates were coated with a mouse monoclonal antibody specific for a C3 neo-epitope expressed in C3b, iC3b, and C3c, but not in the native C3 component. The concentration of the TCC was quantified in a similar EIA with an antibody specific for a neo-epatope expressed only in activated C9 [21J. C3bc and TCC are indicated as arbitrary units (AU)/ml, referred to a standard of zymosan-activated serum defined to contain 1000 AU/ml. Myeloperoxldase and lactoferrin were analysed in plasma by radimmmunological techniques, as described previously [30] .
Statistics
Comparison of the two groups was done using the Mann-Whitney test for continuous variables. Discrete variables were treated by means of contingency tables, with Yates' correction and Fisher's test when one of the expected cell values was less than 5. For the serial measurements of C3bc. TCC, lactoferrin and myeloperoxidase, the sample points were related to the progress of the operation and dlf-fered in each patient. Comparisons at each sample point were therefore not considered relevant. Hence the values were treated individually for each patient, calculating the maximal increase as the difference between the indivxdual peak value (regardless of the sample point), and the value obtained immediately after the start of CPB [20] . The summary measures in the heparin-coated group were compared to the control group using the Mann-Whitney test. Analysas of the time-dependent changes within each group were done using paired Student's t-test and Wllcoxon paired-test [ 18] . The values are expressed as medians with quartiles, or range when indicted. A P-value less than 0.05 was considered significant.
Results
The clinical data are listed in Table 1 . There were no significant differences in demographic or operative parameters, and ischemic and extracorporeal times were nearly identical. The doses of heparin and protamine administered are shown in Table 2 , and reflect the fact that some heparin had to be added to the bolus doses to reach the selected levels of ACT before CPB. The actual heparin and protamine doses in the heparin-coated group were reduced to 30% of the controls. The levels of ACT in the two groups are given in Fig. 1 .
There were no significant differences in postoperative clinical parameters like postoperative blood loss, hemoglobin concentration, cardiac performance or kidney function (Table 3) . Two patients in the control group (not significant) received packed red cells due to postoperative anemia; no other patients were transfused with homologous blood products. In all patients, autotransfusion of the mediastinal shed blood was undertaken during the entire period of investigation. One patient in the control group sustained a minor perioperative myocardial infarction. All patients were extubated early after the operation, and there were no deaths. The mean hematocrits during CPB, and body weights were similar in the two groups, and all figures for the activation products are given uncorrected for hemodilution.
C3 activation products
The C3 activation products C3b, iC3b and C3c (C3bc) increased significantly (P < 0.0001) after the start of CPB in both groups compared to baseline (Fig. 2) . The levels were significantly lower in the heparin-coated group, and the maximal increase of C3bc reached a median of 28 AU/ml (18-40) in Group H, compared to a median of 45 AU/ml (35-65) in the control group (Fig. 3 ) (P=0.01). At 18 h postoperatively, the concentration of C3bc had returned to baseline level.
Terminal complement complex (TCC)
The TCC concentration increased significantly in the control group compared to the baseline level (P < 0.0001). The increase was much less evident in Group H compared to the level seen at the start of CPB, and reached borderline statistical significance (P=0.048) (Fig. 4) . The maximal increase of TCC recorded in Group H was 0.8 AU/ml (0.6-1.2), which was considerably less than the maximal increase in Group C (1.9 AU/ml, 1.5-2.4) (P=0.0007) (Fig. 3) . As for C3bc, the TCC level rapidly decreased after the operation.
Lactoferrin
An increase of lactoferrin release started from the beginning of the operation. During CPB the concentration continued to increase significantly in both groups (P < 0.0001 ) (Fig. 5) . The maximal increase on bypass was median 229 (182-341) ~tg/1 in the heparin-coated group. This was significantly less (P = 0.0002) than the maximal increase of 647 (471-745) btg/1 in Group C (Fig. 3) . In both groups, but more pronounced in the control group, a sudden and significant (P<0.001) decrease of the lactoferrin concentration was seen 2 rain after protamine administration, increasing again 2 h later in Group C. The time interval between termination of CPB and protamine administration was mostly less than 5 mln.
Myeloperoxldase
As with lactoferrin, the release of myeloperoxidase Increased in both groups from the start of surgery (Fig. 6) . However, there were no intergroup differences. The maximal increase on bypass was 91 (84-121) btg/1 in Group H compared to 118 (88-150) gg/1 in Group C (not significant) (Fig. 3 ).
Discussion
Activation of major cascade systems during CPB may be responsible for multiple organ failure, affecting predominantly the lung and kidney function [16, 17] . Complement activation products are considered to play an important role in postperfusion injury [3, 17] , acting via neutrophil granulocytes [12] or directly on the pulmonary vasculature to induce pulmonary hypertension [4] . Recently, Gillinov et al. [8] were able to demonstrate evidence of the pathogenetic role of complement activation in lung injury after CPB in a porcine model. Following infusion of a soluble human complement receptor type 1 (sCR1), a potent inhibitor of complement activation, a significant reduction of pulmonary vascular resistance was documented.
Realizing that complement activation is primarily induced by the blood-surface contact within the oxygenator and tubing set for CPB [32, 34] , efforts have been made to improve the biocompatibility by precoating the surfaces [9, 15, 19] . So far, the Carmeda Bio-Active Surface (CBAS) [19] , using end-point attached covalently bounded heparin, and the Duraflo II surface s [15] , are the only heparin-coated surfaces available for clinical use. Until recently, only the oxygenator and tubings were coated with heparin, leaving the conditions for clinical investigtion partly experimental. In the present study, the effects on bioactive markers could be investigated in a situation where all surfaces of the extracorporeal circuit in contact with blood were heparin-coated, including cannulas, lines, and the cardiotomy reservoir. A significant reduction in complement activation both of the C3 level and of the terminal C5-C9 sequence was demonstrated. Even for the relatively short extracorporeal times of about 50 min, the reduction of complement activation was evident. These results agree with previous studies in patients perfused with circuits partly coated with covalently bounded heparin [6, 34] . For the Duraflo II heparin-coated surfaces, more conflicting data have been presented. Reduction of complement activation was not seen in vitro [29] , but a recent clinical study reported reduced concentration of TCC during bypass and reduction of both C3a and TCC levels after 5 Baxer Healthcare Corp., Irvine, Cahf., USA CPB [26] . Another clinical study of complement and cytokine activation could not demonstrate any significant effects in a Duraflo II-coated group [28] .
Activation of granulocytes and release of cytolytic enzymes contribute to the adverse effects of extracorporeal circulation [13] . To monitor the activation of granulocytes, the release of the glycoproteins lactoferrin and myeloperoxidase were assessed. Both proteins are mediators of the inflammatory response, and increased levels have previously been demonstrated during CPB, both in vitro [13] and in vivo [23, 27, 31] . Lactoferrin is stored in specific cytoplasmatic granulae of the neutrophils [ 13] . In the present study, lactoferrin levels increased rapidly during CPB in both groups. The release was significantly reduced in the heparin-coated group compared to the controls. This corresponds well with the reduced activation seen in other reports studying CBAS-coated oxygenators [2, 6, 33] . The observed rapid decrease of lactoferrin level 2 min after protamine administration has not previously been reported, probably due to different sample points compared to other series. White blood counts were not carried out at this time point, and sequestration of the granulocytes from the circulation can only be suggested. Temporary inactivation or binding of the granulocyte proteins to protamine or the heparin/protamine complex is another possibility, as the effects were most pronounced in the control group which received almost three-fold the amount of protamine.
Myeloperoxidase release did not differ between the groups, in contrast to previous reports [2, 6] . However, as the maximal effects of heparin-coating on myeloperoxidase release were demonstrated to occur late during CPB [6] , the rather limited extracorporeal times in our series may explain the differences. The discrepancy in effects of heparin-coated surfaces on lactoferrin and myeloperoxidase must be due to different mechanisms of release.
Reduced systemic heparinization when perfusing patients with heparin-coated extracorporeal circuits has been proved to be safe, with less postoperative bleeding [1, 35] . The subsequent reduction in protamine administration may have beneficial effects, as protamine is known to cause hemodynamic instability [25] , and may induce toxic effects and complement activation per se [ 14] . Therefore, although changing more than one parameter at the same time -both the levels of heparin/protamine and alternative circuit surfaces -the present clinical model is relevant when studying complement and granulocyte activation. In our patients, the volumes of heparin and protamine were reduced to 30 % of normal doses. No evidence of decreased postoperative bleeding was seen, but the limited number of patients investigated, as well as the modest level of mediastinal drainage in both groups, preclude any significant conclusions.
In conclusion, a complete heparin-coated circuit and low systemic heparinization for CPB were associated with a significant reduction of complement and granulocyte activation. The postoperative morbidity was not affected. However, the patients were all selected low risk cases, and major complications or organ failures were not expected. The clinical importance of both reduced volumes of heparin/protamine and a more biocompatible circuit is suggested to have a beneficial impact in more critically ill patients, but this remains to be documented.
